MACROGENICS, INC. Net Cash Provided by (Used in) Investing Activities, Continuing Operations
MACROGENICS, INC. (MGNX) reported Net Cash Provided by (Used in) Investing Activities, Continuing Operations of -$80.61 million for the 6-month period ending 2019-06-30, per its 10-Q filed 2019-07-31.
Discontinued › Cash Flow
us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations · last filed 2019-07-31
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2019-06-30 was -$10.12M.
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2019-03-31 was -$70.49M, a 463.60% decline year-over-year.
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-12-31 was $45.07M, a 421.75% increase year-over-year.
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for the quarter ending 2018-09-30 was -$6.00K, a 100.13% decline year-over-year.
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2018 was $56.64M, a 27.26% decline from fiscal 2017.
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2017 was $77.88M.
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2016 was -$70.25M.
- MACROGENICS, INC. net cash provided by (used in) investing activities, continuing operations for fiscal 2015 was -$152.11M.
| Period end | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 3 month as first filed | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 6 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 9 month | Net Cash Provided by (Used in) Investing Activities, Continuing Operations 12 month |
|---|---|---|---|---|---|
| 2019-06-30 | -$10.12M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | -$80.61M 10-Q · filed 2019-07-31 | -$35.54M derived: sum of 3 quarters · filed 2019-07-31 | -$35.54M derived: sum of 4 quarters · filed 2019-07-31 | |
| 2019-03-31 | -$70.49M 10-Q · filed 2019-05-01 | -$25.42M derived: sum of 2 quarters · filed 2019-05-01 | -$25.42M derived: sum of 3 quarters · filed 2019-05-01 | -$33.23M derived: sum of 4 quarters · filed 2019-07-31 | |
| 2018-12-31 | $45.07M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $45.07M derived: sum of 2 quarters · filed 2019-02-26 | $37.26M derived: sum of 3 quarters · filed 2019-07-31 | $56.64M 10-K · filed 2019-02-26 | |
| 2018-09-30 | -$6.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | -$7.82M derived: sum of 2 quarters · filed 2019-07-31 | $11.57M 10-Q · filed 2018-11-07 | $20.21M derived: sum of 4 quarters · filed 2019-07-31 | |
| 2018-06-30 | -$7.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-07-31 | $11.58M 10-Q · filed 2019-07-31 | $20.21M derived: sum of 3 quarters · filed 2019-07-31 | $24.68M derived: sum of 4 quarters · filed 2019-07-31 | |
| 2018-03-31 | $19.39M 10-Q · filed 2019-05-01 | $28.03M derived: sum of 2 quarters · filed 2019-05-01 | $32.49M derived: sum of 3 quarters · filed 2019-05-01 | $105.62M derived: sum of 4 quarters · filed 2019-05-01 | |
| 2017-12-31 | $8.64M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | $13.10M derived: sum of 2 quarters · filed 2019-02-26 | $86.23M derived: sum of 3 quarters · filed 2019-02-26 | $77.88M 10-K · filed 2019-02-26 | |
| 2017-09-30 | $4.46M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $77.59M derived: sum of 2 quarters · filed 2018-11-07 | $69.24M 10-Q · filed 2018-11-07 | $71.27M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-06-30 | $73.13M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | $64.77M 10-Q · filed 2018-08-07 | $66.81M derived: sum of 3 quarters · filed 2019-02-26 | $63.64M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2017-03-31 | -$8.36M 10-Q · filed 2018-05-07 | -$6.32M derived: sum of 2 quarters · filed 2019-02-26 | -$9.49M derived: sum of 3 quarters · filed 2019-02-26 | -$66.07M derived: sum of 4 quarters · filed 2019-02-26 | |
| 2016-12-31 | $2.03M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-26 | -$1.13M derived: sum of 2 quarters · filed 2019-02-26 | -$57.72M derived: sum of 3 quarters · filed 2019-02-26 | -$70.25M 10-K · filed 2019-02-26 | |
| 2016-09-30 | -$3.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-08 | -$59.75M derived: sum of 2 quarters · filed 2017-11-08 | -$72.28M 10-Q · filed 2017-11-08 | -$217.97M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-06-30 | -$56.59M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-02 | -$69.12M 10-Q · filed 2017-08-02 | -$214.81M derived: sum of 3 quarters · filed 2018-02-27 | -$217.42M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2016-03-31 | -$12.53M 10-Q · filed 2017-05-03 | -$158.22M derived: sum of 2 quarters · filed 2018-02-27 | -$160.83M derived: sum of 3 quarters · filed 2018-02-27 | -$163.64M derived: sum of 4 quarters · filed 2018-02-27 | |
| 2015-12-31 | -$145.69M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-27 | -$148.30M derived: sum of 2 quarters · filed 2018-02-27 | -$151.11M derived: sum of 3 quarters · filed 2018-02-27 | -$152.11M 10-K · filed 2018-02-27 | |
| 2015-09-30 | -$2.61M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-02 | -$5.42M derived: sum of 2 quarters · filed 2016-11-02 | -$6.42M 10-Q · filed 2016-11-02 | -$8.07M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-06-30 | -$2.81M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-03 | -$3.81M 10-Q · filed 2016-08-03 | -$5.47M derived: sum of 3 quarters · filed 2017-02-28 | -$6.14M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2015-03-31 | -$997.00K 10-Q · filed 2016-05-04 | -$2.65M derived: sum of 2 quarters · filed 2017-02-28 | -$3.33M derived: sum of 3 quarters · filed 2017-02-28 | -$4.12M derived: sum of 4 quarters · filed 2017-02-28 | |
| 2014-12-31 | -$1.66M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-28 | -$2.33M derived: sum of 2 quarters · filed 2017-02-28 | -$3.13M derived: sum of 3 quarters · filed 2017-02-28 | -$3.57M 10-K · filed 2017-02-28 | |
| 2014-09-30 | -$672.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-04 | -$1.47M derived: sum of 2 quarters · filed 2015-11-04 | -$1.91M 10-Q · filed 2015-11-04 | -$2.84M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-06-30 | -$795.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-05 | -$1.24M 10-Q · filed 2015-08-05 | -$2.17M derived: sum of 3 quarters · filed 2016-02-29 | -$3.33M derived: sum of 4 quarters · filed 2016-02-29 | |
| 2014-03-31 | -$447.00K 10-Q · filed 2015-05-06 | -$447.27K 10-Q · filed 2014-05-06 | -$1.37M derived: sum of 2 quarters · filed 2016-02-29 | -$2.53M derived: sum of 3 quarters · filed 2016-02-29 | -$2.98M derived: sum of 4 quarters · filed 2016-02-29 |
| 2013-12-31 | -$924.00K derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-29 | -$2.08M derived: sum of 2 quarters · filed 2016-02-29 | -$2.54M derived: sum of 3 quarters · filed 2016-02-29 | -$2.96M 10-K · filed 2016-02-29 | |
| 2013-09-30 | -$1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-12 | -$1.61M derived: sum of 2 quarters · filed 2014-11-12 | -$2.04M 10-Q · filed 2014-11-12 | ||
| 2013-06-30 | -$450.91K derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-05 | -$876.00K 10-Q · filed 2014-08-05 | |||
| 2013-03-31 | -$425.09K 10-Q · filed 2014-05-06 | ||||
| 2012-12-31 | -$940.00K 10-K · filed 2015-03-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |